---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-26-000048"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2026-08-06T11:01:35+00:00"
generated_at: "2026-08-06T11:05:53.798683+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics Q2 2026 net loss $36.4M; plans Phase 3 for abdakibart in HS in H1 2027

## Summary
- Net loss of $36.4M for Q2 2026, up from $20.8M in Q2 2025; diluted EPS of ($0.83) vs ($1.92).
- Cash, equivalents and investments of $472.2M as of June 30, 2026, expected to fund operations into 2029.
- R&D expenses $23.4M, including $10.0M development milestone for abdakibart; G&A $8.1M.
- Plans to initiate registrational Phase 3 program for abdakibart in hidradenitis suppurativa in H1 2027.
- Expanded pipeline with AVTX-010 (anti-IL-1β antibody); IND submission planned for H1 2027.

## SEC filing metadata
- accession: 0001534120-26-000048
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2026-08-06T11:01:35+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/0001534120-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/avtx-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-26-000048
- JSON: https://secwatch.observer/filing/0001534120-26-000048.json
- Plain text: https://secwatch.observer/filing/0001534120-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.